Skip to main content
Clinical Trials/NCT02487134
NCT02487134Not yet recruitingNot Applicable

Trial of Routine Abdominal Wall Closure Versus Reinforcement With TIGR Matrix Onlay

Karolinska Institutet1 site in 1 country200 target enrollmentStarted: January 1, 2026Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
200
Locations
1
Primary Endpoint
Number of patients with incisional hernia one year after surgery

Study Overview

Brief Summary

Patients with at least two risk factors for incisional hernia undergoing abdominal surgery are eligible for inclusion. After accepting informed consent, patients are randomized into either closing the abdominal wall in a regular way with fascial sutures, or closing with fascial sutures together with placing a TIGR mesh as described. All patients are then monitored for signs of infection, wound rupture, incisional hernias, subcutaneous seroma as well as postoperative symptoms. All patients will be followed for at least 5 years. One year postoperatively, a computer scan is performed to detect asymptomatic incisional hernias.

Detailed Description

Purpose and aims

Wound dehiscence (WD), i.e. the rupturing of the wound along sutures, and incisional hernias (IH), i.e. protrusion of the peritoneum with its contents through the incompletely healed abdominal wall, are common and potentially serious complications after abdominal surgery. Various medical reports indicate that 10-35% of all laparotomy patients suffer from wound complications, leading to extended hospital stay and severe patient morbidity. One approach to mitigate this problem is to use prophylactic surgical mesh at surgery in order to reinforce the suture line. Conventional surgical meshes commonly composed of polypropylene have been successfully demonstrated to reduce the incidence of IH by approximately 70%. However, a synthetic polypropylene mesh is a permanent implant, which may cause chronic inflammation, seroma, pain and infection. Furthermore, if additional surgery is necessary, the implanted polypropylene mesh complicates the procedure.

A solution to the problem of suture reinforcement is the use of a resorbable (biologically degradable) non-permanent mesh that provides structural support during the healing phase, while gradually being absorbed. The TIGR Matrix Surgical Mesh is a completely synthetic resorbable mesh that has the desired properties for use in non-permanent wound reinforcement. The patented TIGR mesh is a weave of two different types of fibers, one fast and one slowly resorb able. This allows for resorbtion to take place in two distinct stages. The fast fiber is a copolymer of glycotide, lactide and trimethylene carbonate, while the slow fiber is a copolymer of lactide and trimethylene carbonate. The two-stage resorbtion of the matrix provides for initial high strength wound support, with gradual loss of mechanical strength as the fibers are degraded. The fast fibers lose mechanical strength after two weeks, with full resorbtion in approximately four months; the slow fibers lose mechanical strength after 9 months, with full resorbtion following 3 years.

The TIGR® Matrix Surgical Mesh has been evaluated in animal models and has been included in clinical studies for abdominal wall repair and breast surgery. A pilot study with the use of the TIGR® mesh has successfully demonstrated its safety in prevention of IH.

In order to extend the clinical use of the TIGR mesh for prophylactic management of WD and IH, we intend to carry out a multicenter randomized clinical study to further evaluate the safety and effectiveness of the TIGR® mesh in patients with increased risk of developing post-surgical wound complications. The intended study will have the impact of widespread prophylactic use of the TIGR mesh in surgery worldwide, resulting in significantly decreased hospital costs and improved quality of life for patients.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Single Group
Primary Purpose
Prevention
Masking
Double (Participant, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Reoperation
  • Age over 80 years
  • Generalised malignant decease (presence of distant metastases at the time of surgery)
  • COPD (Chronic obstructive pulmonary disease). Grade III-IV according to the GOLD classification (FEV1 < 50% of the expected)
  • Serum Albumin level <20 g/l
  • Sepsis. Infection in combination with two or more of the following: abnormal body temperature, heart rate, respiratory rate or blood gas, and white blood cell count.
  • BMI 35-45 (for patients with BMI>45, no additional risk factors are required for inclusion)
  • Hemoglobin <80 g/l
  • Diabetes with secondary complications (angiopathia, nephropathia or neuropathia) and insulin treatment
  • Steroid treatment (with at least 1 mg betamethasone daily or equivalent) for 7 days preoperatively
  • Smoking (at least 10 cigarettes a day for one year)
  • Chemotherapy (last administration within 2 weeks prior to surgery
  • Radiation therapy of the abdominal wall

Exclusion Criteria

  • Presence of mesh after previous surgery
  • Presence of incisional hernia
  • Wound length <10 cm
  • Pregnancy
  • Age < 18 years
  • Infected wounds

Arms & Interventions

Conventional abdominal wall closure

Placebo Comparator

The aponeurosis is closed with continuous PDS 2/0 sutures, with self-locking anchor knots. The stitches are placed 5-8 mm from the wound edge, 4-5 mm apart.

Intervention: Control (Device)

Reinforcement with resorbable mesh

Active Comparator

After closing the aponeurosis with PDS 2/0, a 7 cm wide TIGR Matrix Surgical Mesh is applied on the aponeurosis. The mesh is sutured to the aponeurosis with continuous PDS 2/0, with a wound to suture ratio of 1:4.

Intervention: TIGR Matrix (Device)

Outcomes

Primary Outcomes

Number of patients with incisional hernia one year after surgery

Time Frame: One year

Secondary Outcomes

  • Number of patients with wound dehiscence within one month after surgery(One month)
  • Number of patients with seroma and infection(One month)
  • Number of patients with persisting pain(Five years)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Gabriel Sandblom

Associate Professor

Karolinska Institutet

Study Sites (1)

Loading locations...

Similar Trials